Drug intelligence / Profile preview

ATeGe

Development stage: Unknown
Lead developer: Sanofi
Modality: Antibody-Based Therapeutics

Overview

ATeGe is an immunosuppressive agent, identified as a polyclonal antibody, investigated for its use in liver transplant recipients with pre-transplant renal dysfunction. Its purpose is to provide effective immunosuppression to prevent allograft rejection while potentially mitigating the nephrotoxicity often associated with calcineurin inhibitors, thereby aiming to improve long-term patient prognosis.

Targets

MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on ATeGe.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATeGe.

Explore the full profile